Achieve Life Sciences Inc (SP4P) - Net Assets
Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has net assets worth €33.62 Million EUR (≈ $39.30 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€52.04 Million ≈ $60.84 Million USD) and total liabilities (€18.43 Million ≈ $21.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Achieve Life Sciences Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €33.62 Million |
| % of Total Assets | 64.59% |
| Annual Growth Rate | 1.22% |
| 5-Year Change | -43.95% |
| 10-Year Change | N/A |
| Growth Volatility | 79.37 |
Achieve Life Sciences Inc - Net Assets Trend (2016–2024)
This chart illustrates how Achieve Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore SP4P total assets for the complete picture of this company's asset base.
Annual Net Assets for Achieve Life Sciences Inc (2016–2024)
The table below shows the annual net assets of Achieve Life Sciences Inc from 2016 to 2024. For live valuation and market cap data, see Achieve Life Sciences Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €20.90 Million ≈ $24.43 Million |
+1543.30% |
| 2023-12-31 | €-1.45 Million ≈ $-1.69 Million |
-117.44% |
| 2022-12-31 | €8.30 Million ≈ $9.71 Million |
-70.39% |
| 2021-12-31 | €28.04 Million ≈ $32.78 Million |
-24.79% |
| 2020-12-31 | €37.29 Million ≈ $43.59 Million |
+106.57% |
| 2019-12-31 | €18.05 Million ≈ $21.10 Million |
+14.23% |
| 2018-12-31 | €15.80 Million ≈ $18.47 Million |
+100.56% |
| 2017-12-31 | €7.88 Million ≈ $9.21 Million |
-58.46% |
| 2016-12-31 | €18.97 Million ≈ $22.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Achieve Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20351600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €226.48 Million | 1083.67% |
| Total Equity | €20.90 Million | 100.00% |
Achieve Life Sciences Inc Competitors by Market Cap
The table below lists competitors of Achieve Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CCK Consolidated Holdings Bhd
KLSE:7035
|
$191.78 Million |
|
Acrow Ltd
AU:ACF
|
$191.79 Million |
|
Zinus Inc
KO:013890
|
$191.83 Million |
|
Sailfish Royalty Corp
V:FISH
|
$191.96 Million |
|
Virgin Galactic Holdings Inc
NYSE:SPCE
|
$191.60 Million |
|
Grand Fortune Securities Co Ltd
TWO:6026
|
$191.59 Million |
|
DingZing Advanced Materials Inc.
TW:6585
|
$191.58 Million |
|
Hanmiglobal
KO:053690
|
$191.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Achieve Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,448,000 to 20,899,000, a change of 22,347,000.
- Net loss of 39,827,000 reduced equity.
- New share issuances of 56,076,000 increased equity.
- Other factors increased equity by 6,098,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-39.83 Million | -190.57% |
| Share Issuances | €56.08 Million | +268.32% |
| Other Changes | €6.10 Million | +29.18% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Achieve Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.03x to 5.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €131.89 | €3.60 | x |
| 2018-12-31 | €47.02 | €3.60 | x |
| 2019-12-31 | €12.24 | €3.60 | x |
| 2020-12-31 | €6.10 | €3.60 | x |
| 2021-12-31 | €2.97 | €3.60 | x |
| 2022-12-31 | €0.46 | €3.60 | x |
| 2023-12-31 | €-0.07 | €3.60 | x |
| 2024-12-31 | €0.60 | €3.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Achieve Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -190.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.85x
- Recent ROE (-190.57%) is below the historical average (-141.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -106.13% | -397.65% | 0.18x | 1.45x | €-22.03 Million |
| 2017 | -134.32% | 0.00% | 0.00x | 1.26x | €-11.37 Million |
| 2018 | -80.29% | 0.00% | 0.00x | 1.21x | €-14.27 Million |
| 2019 | -90.83% | 0.00% | 0.00x | 1.17x | €-18.20 Million |
| 2020 | -39.51% | 0.00% | 0.00x | 1.08x | €-18.46 Million |
| 2021 | -118.22% | 0.00% | 0.00x | 1.69x | €-35.96 Million |
| 2022 | -510.06% | 0.00% | 0.00x | 3.61x | €-43.18 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-29.67 Million |
| 2024 | -190.57% | 0.00% | 0.00x | 1.85x | €-41.92 Million |
Industry Comparison
This section compares Achieve Life Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $698,488,333
- Average return on equity (ROE) among peers: -63.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Achieve Life Sciences Inc (SP4P) | €33.62 Million | -106.13% | 0.55x | $191.64 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sop… Read more